These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35230200)

  • 1. Pharmacotherapeutic combinations for the treatment of Alzheimer's disease.
    Nagata T; Shinagawa S; Nakajima S; Noda Y; Mimura M
    Expert Opin Pharmacother; 2022 Apr; 23(6):727-737. PubMed ID: 35230200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
    Schmidt R; Hofer E; Bouwman FH; Buerger K; Cordonnier C; Fladby T; Galimberti D; Georges J; Heneka MT; Hort J; Laczó J; Molinuevo JL; O'Brien JT; Religa D; Scheltens P; Schott JM; Sorbi S
    Eur J Neurol; 2015 Jun; 22(6):889-98. PubMed ID: 25808982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment strategies for Alzheimer's disease: is there a hope?
    Aprahamian I; Stella F; Forlenza OV
    Indian J Med Res; 2013 Oct; 138(4):449-60. PubMed ID: 24434253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
    Buccellato FR; D'Anca M; Tartaglia GM; Del Fabbro M; Scarpini E; Galimberti D
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying drugs in Alzheimer's disease.
    Ghezzi L; Scarpini E; Galimberti D
    Drug Des Devel Ther; 2013 Dec; 7():1471-8. PubMed ID: 24353405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
    Joe E; Ringman JM
    BMJ; 2019 Dec; 367():l6217. PubMed ID: 31810978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
    Khoury R; Patel K; Gold J; Hinds S; Grossberg GT
    Drugs Aging; 2017 Nov; 34(11):811-820. PubMed ID: 29116600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.
    Zhang F; Zhong RJ; Cheng C; Li S; Le WD
    Acta Pharmacol Sin; 2021 Sep; 42(9):1382-1389. PubMed ID: 33268824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
    Calhoun A; King C; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease.
    Jürgenson M; Zharkovskaja T; Noortoots A; Morozova M; Beniashvili A; Zapolski M; Zharkovsky A
    J Pharm Pharmacol; 2019 Nov; 71(11):1695-1705. PubMed ID: 31531878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
    Parnetti L; Senin U; Mecocci P
    Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Alzheimer's disease: current status and new perspectives.
    Scarpini E; Scheltens P; Feldman H
    Lancet Neurol; 2003 Sep; 2(9):539-47. PubMed ID: 12941576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies.
    Cummings JL
    Rev Neurol Dis; 2007; 4(2):57-62. PubMed ID: 17609636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.